INTRODUCTION
Since 1977 the epidemiological characteristics of the influenza A virus have been different from those described in virological, serological, and epidemiological studies carried out from 1933 to 1977. The H1N1 virus has remained throughout the world as a common infective agent alongside the H3N2 virus, which had the monopoly from 1968 to 1977. This is in contrast with the situation in 1957, when the H1N1 virus was succeeded by the H2N2 virus as an epidemic agent, and in 1968, when the H3N2 virus took over from H2N2. Both former viruses disappeared without trace in human populations. Currently, the H3N2 virus is still circulating widely as an epidemic agent in all age groups in the world population.
When the H1N1 virus reappeared in The Netherlands in 1977, scrological studies revealed that individuals born after 1949 did not possess antibodies against this virus, although on epidemiological grounds this would have been expected solely for persons born after 1957 (Masurel & Andre, 1978) . Subsequently, it was found that 75% of people aged 70 years or older possessed no antibodies at all against the H1N1 virus, and only 2% showed a protective level of antibodies (Masurel, 1979) .
The present study was directed towards two population groups of young people born after 1957 who had been exposed in their lifetime to influenza epidemics caused by H2N2 or H3N2 virus only. Part of the study group had been immunized in 1976 and/or 1977 with the A/New Jersey/8/76 (H1N1) (A/NJ/76) virus (Masurel, de Jong & Verhoeff, 1977) . In retrospective studies it has been found that the agent of the 1918-1919 pandemic, which was similar or identical to the A/Swine/Iowa/15/30(H1N1) virus, is clearly related to all influenza A viruses emerging from 1918 to 1957, including the H1N1 viruses prevailing from 1946 to 1956 (Masurel, 1962) . The results presented here show the serological response to influenza A/USSR/77 vaccine in individuals born after 1957 with or without a history of previous A/NJ/76 immunization.
MATERIALS AND METHODS

Study group
Participants to the study were 269 pupils of the Harbour and Transport Training Institute in Rotterdam (group A) and 109 mentally handicapped patients of the Dr Mr Willem van den Bergh Foundation at Noordwijk (group B), aged 13-20 years and 11-21 years, respectively. In both groups the parents' consent was obtained before the trial. In group A, 145 pupils had been immunized in 1976 with a trivalent vaccine containing 20 /ig HA A/New Jersey/8/76 (H1N1), 20 /<g HA A/Victoria/3/75 (H3N2) and 18 fig HA B/Hong Kong/8/73 virus. This vaccine had also been administered to 97 patients of group B in 1976 and 1977 (Masurel, de Jong & Verhoeff, 1977) . Age distribution among different vaccine-dose groups is similar for participants immunized or not immunized previously with A/NJ/76 virus.
Immunization
In February were given a booster dose. Vaccines were administered intramuscularly in the upper arm.
After primary immunization, participants of group A recorded local reactions, redness, swelling, and pain at the injection site, and systemic reactions, headache, fever and malaise. In group B redness, swelling, and tenderness at the injection site were monitored and body temperature was measured by the medical staff.
For both groups, local reactions were considered positive if one or more local symptoms were reported. Systemic reactions were scored positive in group B if the body temperature was over 37*5 °C, and in group A if one or more systemic reactions were reported.
Serological studies
Blood samples were collected from all participants on the day of primary immunization (SI) and four weeks later (SII). From 176 participants sera were sampled three weeks after booster immunization (SIII). All sera from each participant were simultaneously examined in the haemagglutination inhibition (HI) test for antibodies against the HlNl virus A/Hong Kong/117/77 (identical to the vaccine strain A/USSR/77) and against the A/NJ/76 (HlNl) virus present in the influenza vaccines of previous years. Before testing, the sera were treated with Vibrio ckolerae filtrate for 18 h at 37 °C and subsequently heated at 56 °C for 1 h to remove non-specific inhibitors (Masurel, 1969) . In all experiments reference antisera were included. In establishing the geometric mean titre (OMT) an HI titre of < 9 was recorded as 8, and of > 2150 as 2200. A titre ^ 100 found by our titration method was regarded as protective (Wesselius-de Casparis, Masurel & Kerrebijn, 1972 ). Table 1 shows the results of the HI test using the influenza virus A/Hong Kong/117/77 (HlNl) on sera of groups A and B, obtained before, after primary, and after booster immunization with the antigenically identical virus A/USSR/77 (HlNl). Group A is divided in three subgroups according to the amount of virus in the vaccine given. Furthermore, distinction has been made in groups A and B between subjects that did or did not receive a vaccine containing A/NJ/76 virus in 1976 and/or 1977. All pre-immunization sera (SI) were negative with regard to HlNl antibody.
RESULTS
In group A, after primary immunization with 10 fig, 20 fig, or 40 fig HA A/USSR/77 virus the serological responses showed little difference between subjects that had or had not received A/NJ/76 virus containing vaccine previously. After booster immunization GMTs were 1-5-fold to 3-fold higher, and frequency of titres above 100 1-5-fold to 2-fold higher in the participants not previously immunized with A/NJ/76 virus.
In group B, after booster immunization patients immunized previously with A/NJ/76 virus showed a response similar to that of participants after primary immunization with A/USSR/77 virus without previous A/NJ/76 immunization. After booster immunization GMT& were 4-fold higher and frequency of titres above • t See Table 1 . The percentage of HI titres above 100 is shown in the last column of Table 1 Responses with regard to A/NJ/76 virus in participants not immunized previously with this .virus were persistently low after primary or booster immunization with A/USSR/77 virus.
In Table 3 local and systemic side effects in groups A and B after primary immunization with A/USSR/77 virus are presented. In group A local reactions were principally manifested by pain at the injection site and systemic reactions by headache. The frequency of combined local and systemic side effects increased with the dose of virus in the vaccine, both in individuals primed or unprimed for A/NJ/76 virus. The percentage of participants in which side effects were absent was higher in the vaccine-dose groups that had not been immunized with A/NJ/76 virus.
In group B local and systemic side effects were less frequent than in group A. All body temperatures measured remained below 38-5 °C, most being below 38 °C. Both systemic and local reactions were reported in 2 and 8%, respectively, of patients immunized or not immunized previously with A/NJ/76 virus. Percentages of patients in which side effects were absent were identical in both contingents. DISCUSSION Pre-immunization antibody titres against the A/NJ/76 virus were detected in 107 sera (77 %) of participants of group A and in 86 sera (90 %) of patients of group B. These titres had been achieved by immunization with this virus in preceding years. The A/NJ/76 antibodies were boosted to a protective level (^ 100) (Wesselius-de Casparis, Masurel & Kerrebijn, 1972) by A/USSR/77 immunization in 85-100% of participants in group A and in 94% of participants in group B. Volunteers who had not been primed for A/NJ/76 virus showed no or minor responses against this virus after immunization with A/USSR/77 virus. This phenomenon of immune response after immunization with an antigen (A/USSR/77) directed against a related antigen (A/NJ/76) to which the individual has already been exposed during preceding years, was described for the first time by Francis and co-workers, who called it 'original antigenic sin' (Davenport, Hennessy & Francis, 1953; Francis, 1955; Davenport & Hennessy, 1956) .
The boosting described above explains the frequent presence of high antibody levels against the A/Swine/15/30 virus and the related A/NJ/76 virus in people now aged 53 years or more (Masurel, 1976) Volunteers in group A, immunized with the A/NJ/76 virus in 1976, showed a distinctly lower response to A/USSR/77 virus than vaccinees who did not receive A/NJ/76 vaccine previously. This was especially so after booster immunization with A/USSR/77 virus. It was even more evident for the 95 previously immunized patients of group B, 71 (75%) of whom had been immunized both in 1976 and in 1977. Presumably, the homologous antibody production after immunization with A/USSR/77 virus was inhibited by a blocking of the immune system during previous years by the related A/NJ/76 virus (Virelizier, Allison & Schild, 1974; Laver, Downie & Webster, 1976) . A parallel observation was reported by Hoskins et al. (1979) in a study in which reimmunization with a later strain did not afford protection against infection with the epidemic influenza A virus.
The reactivity of the whole virus vaccine established in the present study comprised side-effects mostly consisting of slight symptomsonly. However, 30-70% of participants in the various groups did experience some reaction. Gross et al. (1977) observed that prior influenza immunization reduces reactions following subsequent immunization with related antigens. In our group A it is remarkable that pupils receiving an influenza vaccine for the first time indicate less reactions than those immunized previously in 1976. In group B this difference was not found. This may be explained by the occurrence of a 4 memory-ejfect' caused by the previous A/NJ/76 immunization in the respective participants of group A, which could not have happened in group B, since an objective registration was carried out.
The conclusions from this study are that individuals unprimed for A/USSR/77 virus should be immunized twice to afford a protective level of antibody. This is in agreement with findings in other studies (Feery et al. 1979; Nicholson et al. 1979; Potter et al. 1980) . After two doses of A/USSR/77 vaccine, subjects primed for the related A/NJ/76 virus possess a lower degree of protection against A/USSR/77 virus than those unprimed for A/NJ/76 virus. Individuals exposed through immunization to the A/NJ/76 virus need only a single heterologous booster dose of A/USSR/77 virus to be protected against infection with A/NJ/76 virus, should the latter become epidemic (Masurel, 1976) .
